StateHouse Holdings Past Earnings Performance
Past criteria checks 0/6
StateHouse Holdings's earnings have been declining at an average annual rate of -45.4%, while the Pharmaceuticals industry saw earnings growing at 59.3% annually. Revenues have been growing at an average rate of 23.4% per year.
Key information
-45.4%
Earnings growth rate
3.6%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 23.4% |
Return on equity | n/a |
Net Margin | -56.4% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By StateHouse Holdings Inc.'s (CSE:STHZ) Revenues Despite 40% Price Jump
Aug 10Slammed 42% StateHouse Holdings Inc. (CSE:STHZ) Screens Well Here But There Might Be A Catch
Mar 05The Market Lifts StateHouse Holdings Inc. (CSE:STHZ) Shares 175% But It Can Do More
Jan 04Even With A 200% Surge, Cautious Investors Are Not Rewarding StateHouse Holdings Inc.'s (CSE:STHZ) Performance Completely
Sep 01StateHouse Holdings Inc.'s (CSE:STHZ) Shares Leap 200% Yet They're Still Not Telling The Full Story
Sep 01Revenue & Expenses Breakdown
How StateHouse Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 101 | -57 | 51 | 0 |
31 Dec 23 | 101 | -50 | 53 | 0 |
30 Sep 23 | 101 | -226 | 57 | 0 |
30 Jun 23 | 106 | -229 | 62 | 0 |
31 Mar 23 | 116 | -243 | 70 | 0 |
31 Dec 22 | 108 | -243 | 65 | 0 |
30 Sep 22 | 98 | -72 | 56 | 0 |
30 Jun 22 | 84 | -49 | 45 | 0 |
31 Mar 22 | 65 | -34 | 33 | 0 |
31 Dec 21 | 60 | -26 | 31 | 0 |
30 Sep 21 | 58 | -4 | 32 | 0 |
30 Jun 21 | 59 | -9 | 32 | 0 |
31 Mar 21 | 59 | -12 | 30 | 0 |
31 Dec 20 | 60 | -12 | 28 | 0 |
30 Sep 20 | 59 | -52 | 28 | 0 |
30 Jun 20 | 53 | -51 | 27 | 0 |
31 Mar 20 | 50 | -55 | 31 | 0 |
31 Dec 19 | 47 | -49 | 32 | 0 |
30 Sep 19 | 36 | -5 | 27 | 0 |
30 Jun 19 | 34 | -8 | 27 | 0 |
31 Mar 19 | 27 | -8 | 21 | 0 |
31 Dec 18 | 21 | -18 | 19 | 0 |
30 Sep 18 | 25 | -18 | 20 | 0 |
31 Dec 17 | 15 | -6 | 11 | 0 |
31 Dec 16 | 6 | -3 | 7 | 0 |
Quality Earnings: STHZ is currently unprofitable.
Growing Profit Margin: STHZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STHZ is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare STHZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STHZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: STHZ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.